Neurocrine Biosciences (NBIX) Accumulated Expenses (2010 - 2019)

Neurocrine Biosciences has reported Accumulated Expenses for 10 years, with the latest figure at $38.9 million in Q4 2019.

• For the quarter ending Q4 2019, Accumulated Expenses rose 42.43% year-over-year to $38.9 million; the trailing twelve-month figure through Dec 2019 stood at $38.9 million (up 42.43% YoY), and the FY2019 full-year result was $38.9 million, up 42.43% from the prior year.
• Accumulated Expenses for Q4 2019 stood at $38.9 million, up from $27.3 million in the prior quarter.
• The five-year high for Accumulated Expenses was $38.9 million in Q4 2019, with the low at $9.6 million in Q4 2016.
• Historically, Accumulated Expenses has averaged $19.5 million across 5 years, with a median of $18.7 million in 2015.
• Annual changes were most pronounced in 2016 — Accumulated Expenses slumped 49.78% — and 2017, when it soared 160.5%.
• Neurocrine Biosciences' Accumulated Expenses stood at $19.0 million in 2015, then plunged by 49.78% to $9.6 million in 2016, then soared by 160.5% to $24.9 million in 2017, then climbed by 9.8% to $27.3 million in 2018, then jumped by 42.43% to $38.9 million in 2019.
• The last three Accumulated Expenses figures came in at $38.9 million (Q4 2019), $27.3 million (Q4 2018), and $24.9 million (Q4 2017), per Business Quant data.